Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker

被引:0
作者
Yanxing Li
Wentao Gao
Zhen Yang
Zhenwei Hu
Jianjun Li
机构
[1] Xi’an Jiaotong University Health Science Center,Department of Cardiology
[2] Jincheng People’s Hospital Affiliated to Changzhi Medical College,undefined
来源
Scientific Reports | / 14卷
关键词
MCM4; Multi-omics; Pan-cancer; Bioinformatics; Immune infiltration; Prognosis; Biomarker;
D O I
暂无
中图分类号
学科分类号
摘要
Minichromosome Maintenance Complex Component 4 (MCM4) is a vital component of the mini-chromosome maintenance complex family, crucial for initiating the replication of eukaryotic genomes. Recently, there has been a growing interest in investigating the significance of MCM4 in different types of cancer. Despite the existing research on this topic, a comprehensive analysis of MCM4 across various cancer types has been lacking. This study aims to bridge this knowledge gap by presenting a thorough pan-cancer analysis of MCM4, shedding light on its functional implications and potential clinical applications. The study utilized multi-omics samples from various databases. Bioinformatic tools were employed to explore the expression profiles, genetic alterations, phosphorylation states, immune cell infiltration patterns, immune subtypes, functional enrichment, disease prognosis, as well as the diagnostic potential of MCM4 and its responsiveness to drugs in a range of cancers. Our research demonstrates that MCM4 is closely associated with the oncogenesis, prognosis and diagnosis of various tumors and proposes that MCM4 may function as a potential biomarker in pan-cancer, providing a deeper understanding of its potential role in cancer development and treatment.
引用
收藏
相关论文
共 193 条
[1]  
Pavlova NN(2022)The hallmarks of cancer metabolism: Still emerging Cell Metabol. 34 355-377
[2]  
Zhu J(2022)Hallmarks of cancer: New dimensions Cancer Discov. 12 31-46
[3]  
Thompson CB(2017)New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles Cancer Gene Ther. 24 233-243
[4]  
Hanahan D(2018)Tumor-treating fields: A fourth modality in cancer treatment Clin. Cancer Res. 24 266-275
[5]  
Zaimy MA(2022)Big data in basic and translational cancer research Nat. Rev. Cancer 22 625-639
[6]  
Mun EJ(2021)Conserved pan-cancer microenvironment subtypes predict response to immunotherapy Cancer Cell 39 845-865.e847
[7]  
Babiker HM(2020)A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling Cell Res. 30 745-762
[8]  
Weinberg U(2013)The cancer genome Atlas pan-cancer analysis project Nat. Genet. 45 1113-1120
[9]  
Kirson ED(2009)Concerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensing Cell 139 719-730
[10]  
Von Hoff DD(2011)The structural basis for MCM2-7 helicase activation by GINS and Cdc45 Nat. Struct. Mol. Biol. 18 471-477